Private partnerships
Partnering and collaborating in the life science industry is essential for the development of innovative drug candidates. Since the beginning, Â鶹Æƽâ°æ has worked closely with several academic institutions, researchers, hospitals and private companies to build a strong portfolio in various therapeutic areas.
Indeed, Â鶹Æƽâ°æ has developed an innovative and disruptive drug discovery engine allowing to discover patentable molecules directed against new therapeutic intracellular targets.
Thus, Â鶹Æƽâ°æ is open to collaborate and partner to develop some of its molecules with different chemistry patterns coming from its unique approach. Please do not hesitate to contact us if you are interested.
Our current collaborations
Novadiscovery
Â鶹Æƽâ°æ has signed a collaboration agreement with Novadiscovery, which consists in accelerating and de-risking the clinical development of EYP001, a bile acid receptor agonist (the farsenoid X nuclear receptor or FXR).
Our past collaborations
Charles River
Charles River Laboratories International and Â鶹Æƽâ°æ have initiated a collaboration to identify the mode of action of Â鶹Æƽâ°æ’s lead preclinical chemical series, EYP002, using Charles River’s newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology.
Contact
Â鶹Æƽâ°æ
BIOSERRA 1 Bâtiment B
60 avenue Rockefeller
69008 LYON, FRANCE
Mail: contact@enyopharma.com
Latest Press Release 